NOVARTIS A G's ticker is NVS and the CUSIP is 66987V109. A total of 1,008 filers reported holding NOVARTIS A G in Q4 2017. The put-call ratio across all filers is 0.74 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $278,000 | -65.0% | 3,194 | -63.3% | 0.02% | -64.3% |
| Q2 2019 | $794,000 | -16.1% | 8,701 | -11.6% | 0.04% | -12.5% |
| Q1 2019 | $946,000 | +12.1% | 9,838 | +0.0% | 0.05% | -2.0% |
| Q4 2018 | $844,000 | -12.3% | 9,836 | -11.9% | 0.05% | +16.7% |
| Q3 2018 | $962,000 | +14.1% | 11,162 | +0.0% | 0.04% | +100.0% |
| Q2 2018 | $843,000 | -10.1% | 11,160 | -3.9% | 0.02% | -12.5% |
| Q1 2018 | $938,000 | +50.8% | 11,607 | +56.8% | 0.02% | +84.6% |
| Q4 2017 | $622,000 | +13.3% | 7,403 | +15.7% | 0.01% | +8.3% |
| Q3 2017 | $549,000 | +155.3% | 6,398 | +148.2% | 0.01% | +140.0% |
| Q2 2017 | $215,000 | -4.4% | 2,578 | -1.2% | 0.01% | 0.0% |
| Q4 2015 | $225,000 | +1.4% | 2,610 | +8.2% | 0.01% | -37.5% |
| Q3 2015 | $222,000 | -6.3% | 2,412 | 0.0% | 0.01% | -20.0% |
| Q2 2015 | $237,000 | +10.7% | 2,412 | +11.1% | 0.01% | +25.0% |
| Q1 2015 | $214,000 | -3.6% | 2,171 | -9.5% | 0.01% | -11.1% |
| Q4 2014 | $222,000 | – | 2,399 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MANAGED ASSET PORTFOLIOS, LLC | 332,962 | $27,452,000 | 7.32% |
| Mawer Investment Management Ltd. | 7,721,327 | $636,623,000 | 5.86% |
| Martin Investment Management, LLC | 133,246 | $10,986,000 | 5.56% |
| SCHARF INVESTMENTS, LLC | 1,330,175 | $109,673,000 | 5.48% |
| Hansberger Growth Investors, LP | 46,663 | $3,847,000 | 5.19% |
| Bain Capital Public Equity Management II, LLC | 440,233 | $36,297,000 | 4.25% |
| First Fiduciary Investment Counsel, Inc. | 187,633 | $15,470,000 | 4.10% |
| GARLAND CAPITAL MANAGEMENT INC | 53,555 | $4,416,000 | 4.02% |
| Lowell Blake & Associates Inc. | 37,219 | $3,069,000 | 3.94% |
| PRENTISS SMITH & CO INC | 68,027 | $5,609,000 | 3.89% |